GLP-1 Receptor Agonist Injections for Weight Loss: A Complete UK Guide
GLP-1 receptor agonist injections are licensed in the UK for weight management and have strong clinical trial evidence behind them. This guide covers how they work, what the evidence shows, who is eligible, and what to expect.
What are GLP-1 receptor agonist injections?
GLP-1 receptor agonist injections are a class of once-weekly prescription medicines licensed by the MHRA for chronic weight management in adults with obesity or overweight with weight-related health conditions. They were developed from research into gut hormones and represent a significant advance in medical weight management.
How do they work?
GLP-1 (glucagon-like peptide-1) is a hormone produced in the gut after eating that signals fullness to the brain, slows the rate at which the stomach empties, and reduces appetite. These medicines mimic this hormone but with a much longer duration of action — allowing once-weekly dosing rather than the multiple daily injections required by earlier GLP-1 medicines.
The net effect is a significant and sustained reduction in appetite and calorie intake, leading to meaningful weight loss over time.
What does the evidence show?
The STEP clinical trial programme provides robust evidence for this class of medicine in weight management:
- STEP 1 — In adults with obesity or overweight without diabetes, participants achieved an average weight loss of 14.9% of body weight over 68 weeks, compared with 2.4% in the placebo group. Over 86% of participants achieved at least 5% weight loss.
- STEP 2 — In adults with type 2 diabetes, average weight loss was 9.6% — significantly greater than placebo and greater than most other approved treatments for this population.
- STEP 4 — Participants who continued treatment after an initial 20-week run-in maintained their weight loss, while those switched to placebo regained approximately two-thirds of the weight lost — confirming that ongoing treatment is needed to maintain results.
- SELECT trial — In adults with established cardiovascular disease and obesity, treatment reduced the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) by 20% compared with placebo — the first weight management medicine to demonstrate cardiovascular benefit in a large randomised trial.
Dose escalation
Treatment is started at a low dose and increased gradually over several months to the maintenance dose. This gradual increase is designed to minimise gastrointestinal side effects. Your clinician will guide you through the escalation schedule.
What are the common side effects?
Gastrointestinal side effects — nausea, vomiting, diarrhoea, constipation, and abdominal discomfort — are the most common and are most pronounced during dose escalation. They typically improve as the body adjusts. Eating smaller meals, avoiding high-fat foods, and staying well hydrated can help manage these effects. Serious side effects are uncommon and include pancreatitis and gallbladder disease.
Oral options
Oral formulations of GLP-1 receptor agonists are also now available in the UK, offering the same class of medicine in tablet form for patients who prefer not to inject. The dose escalation schedule differs from the injection, and the tablets must be taken on an empty stomach with a small amount of water.
Book a consultation with Weight Loss Wales to find out whether this treatment is right for you.
Medical disclaimer: The information in this article is for general educational purposes only and does not constitute medical advice. It should not replace a consultation with a qualified healthcare professional. If you have concerns about your health or weight, please speak to your GP or a specialist.
Related articles
Want personalised support?
Our doctor-led team can help you create a plan that works for you. A clinician will contact you within 12 hours.
Start your consultation